Want to join the conversation?
$LLY 2Q15 PR: Revenue was $4978.7MM. GAAP net income was $600.8MM or $0.56 per diluted share. Revenue grew 1% with inclusion of Novartis Animal Health & higher volume for several products, including Cyramza and Trulicity; these factors were largely offset by unfavorable effect of FX rates & residual impact of Cymbalta and Evista patent expirations.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.